Literature DB >> 3569930

Pharmacokinetics of a sustained-release product of indomethacin in the elderly.

B Bruguerolle, G Barbeau, P M Bélanger, G Labrecque.   

Abstract

The pharmacokinetics of indomethacin (Indo) was studied in 10 healthy elderly male volunteers (age 67-81 years) following the oral administration of a single 75-mg dose of a sustained release form of Indo. The total and free plasma and erythrocyte concentrations of Indo were determined by a specific high-pressure liquid chromatographic method. A maximum concentration (Cmax) of 4.28 +/- (SE) 0.43 micrograms/ml was reached after 1.85 +/- 0.22 h. The area under the plasma concentration versus time curve (AUC) was 22.83 +/- 2.70 micrograms ml-1 h and the plasma elimination half-life was 4.34 +/- 0.64 h. The maximum concentration of Indo in the red blood cells was 0.123 +/- 0.013 microgram/ml and was obtained at 1.95 +/- 0.14 h after drug administration. The erythrocyte concentrations of Indo represented 2.4% of the total plasma levels of Indo whereas only 1.3% of the drug was unbound to plasma proteins. The Cmax and AUC values determined in the elderly were approximately double the values reported in young adults for the same dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3569930     DOI: 10.1159/000212802

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  3 in total

1.  Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase.

Authors:  C J Fowler; M Börjesson; G Tiger
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

Review 2.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Microglial responses to amyloid beta peptide opsonization and indomethacin treatment.

Authors:  Ronald Strohmeyer; Carl J Kovelowski; Diego Mastroeni; Brian Leonard; Andrew Grover; Joseph Rogers
Journal:  J Neuroinflammation       Date:  2005-08-19       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.